B7-H4 Immune Checkpoint Protein Affects Viability and Targeted Therapy of Renal Cancer Cells

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 May 14

PMID 35563753

Authors

Maite Emaldi

Caroline E Nunes-Xavier

Affiliations

Soon will be listed here.

Abstract

Targeted therapy in combination with immune checkpoint inhibitors has been recently implemented in advanced or metastatic renal cancer treatment. However, many treated patients either do not respond or develop resistance to therapy, making alternative immune checkpoint-based immunotherapies of potential clinical benefit for specific groups of patients. In this study, we analyzed the global expression of B7 immune checkpoint family members (PD-L1, PD-L2, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6, and B7-H7) in human renal cancer cells (Caki-1, A-498, and 786-O cell lines) upon treatment with clinically relevant targeted drugs, including tyrosine kinase inhibitors (Axitinib, Cabozantinib, and Lenvatinib) and mTOR inhibitors (Everolimus and Temsirolimus). Gene expression analysis by quantitative PCR revealed differential expression patterns of the B7 family members in renal cancer cell lines upon targeted drug treatments. B7-H4 gene expression was upregulated after treatment with various targeted drugs in Caki-1 and 786-O renal cancer cells. Knocking down the expression of B7-H4 by RNA interference (RNAi) using small interfering RNA (siRNA) decreased renal cancer cell viability and increased drug sensitivity. Our results suggest that B7-H4 expression is induced upon targeted therapy in renal cancer cells and highlight B7-H4 as an actionable immune checkpoint protein in combination with targeted therapy in advanced renal cancer cases resistant to current treatments.

Citing Articles

Impact of B7-H3 expression on metastasis, immune exhaustion and JAK/STAT and PI3K/AKT pathways in clear cell renal cell carcinoma.

Emaldi M, Rey-Iborra E, Marin A, Mosteiro L, Lecumberri D, Oyjord T Oncoimmunology. 2024; 13(1):2419686.

PMID: 39621555 PMC: 11540085. DOI: 10.1080/2162402X.2024.2419686.

A functional role for glycosylated B7-H5/VISTA immune checkpoint protein in metastatic clear cell renal cell carcinoma.

Emaldi M, Alamillo-Maeso P, Rey-Iborra E, Mosteiro L, Lecumberri D, Pulido R iScience. 2024; 27(9):110587.

PMID: 39262813 PMC: 11388181. DOI: 10.1016/j.isci.2024.110587.

B7H4 Role in Solid Cancers: A Review of the Literature.

Dawidowicz M, Kot A, Mielcarska S, Psykala K, Kula A, Waniczek D Cancers (Basel). 2024; 16(14).

PMID: 39061159 PMC: 11275172. DOI: 10.3390/cancers16142519.

From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review.

Regmi M, Wang Y, Liu W, Dai Y, Liu S, Ma K J Exp Clin Cancer Res. 2024; 43(1):47.

PMID: 38342925 PMC: 10860318. DOI: 10.1186/s13046-024-02973-5.

Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands.

Kamali A, Bautista J, Eisenhut M, Hamedifar H Ther Adv Vaccines Immunother. 2023; 11:25151355231192043.

PMID: 37662491 PMC: 10469281. DOI: 10.1177/25151355231192043.

References

Prasad D, Richards S, Mai X, Dong C . B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity. 2003; 18(6):863-73. DOI: 10.1016/s1074-7613(03)00147-x. View

Wu F, Wang J, Ke X . Knockdown of B7-H6 inhibits tumor progression and enhances chemosensitivity in B-cell non-Hodgkin lymphoma. Int J Oncol. 2016; 48(4):1561-70. DOI: 10.3892/ijo.2016.3393. View

Tringler B, Zhuo S, Pilkington G, Torkko K, Singh M, Lucia M . B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res. 2005; 11(5):1842-8. DOI: 10.1158/1078-0432.CCR-04-1658. View

Hudson K, Cross N, Jordan-Mahy N, Leyland R . The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Front Immunol. 2020; 11:568931. PMC: 7609400. DOI: 10.3389/fimmu.2020.568931. View

Aurtenetxe O, Zaldumbide L, Erramuzpe A, Lopez R, Lopez J, Cortes J . DUSP5 expression associates with poor prognosis in human neuroblastoma. Exp Mol Pathol. 2018; 105(3):272-278. DOI: 10.1016/j.yexmp.2018.08.008. View

Buczek M, Escudier B, Bartnik E, Szczylik C, Czarnecka A . Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. Biochim Biophys Acta. 2013; 1845(1):31-41. DOI: 10.1016/j.bbcan.2013.10.001. View

Ljungberg B, Sundqvist P, Lindblad P, Kjellman A, Thorstenson A, Hellstrom M . Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting. Scand J Urol. 2020; 54(6):487-492. DOI: 10.1080/21681805.2020.1815833. View

Meyer M, DeNardo D . Better Together: B7S1 Checkpoint Blockade Synergizes with anti-PD1. Immunity. 2018; 48(4):621-623. DOI: 10.1016/j.immuni.2018.03.029. View

Brodaczewska K, Szczylik C, Fiedorowicz M, Porta C, Czarnecka A . Choosing the right cell line for renal cell cancer research. Mol Cancer. 2016; 15(1):83. PMC: 5168717. DOI: 10.1186/s12943-016-0565-8. View

10.

Li H, Piao L, Liu S, Cui Y, Xuan Y . B7-H4 is a potential prognostic biomarker of prostate cancer. Exp Mol Pathol. 2020; 114:104406. DOI: 10.1016/j.yexmp.2020.104406. View

11.

Shen L, Qian Y, Wu W, Weng T, Wang F, Hong B . B7-H4 is a prognostic biomarker for poor survival in patients with pancreatic cancer. Hum Pathol. 2017; 66:79-85. DOI: 10.1016/j.humpath.2017.05.023. View

12.

Bedke J, Albiges L, Capitanio U, Giles R, Hora M, Lam T . The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. Eur Urol. 2021; 80(4):393-397. DOI: 10.1016/j.eururo.2021.04.042. View

13.

Ni L, Dong C . New B7 Family Checkpoints in Human Cancers. Mol Cancer Ther. 2017; 16(7):1203-1211. PMC: 5568666. DOI: 10.1158/1535-7163.MCT-16-0761. View

14.

Huang J, Hsieh J . The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age. Semin Nephrol. 2020; 40(1):28-41. PMC: 8858035. DOI: 10.1016/j.semnephrol.2019.12.004. View

15.

Azuma T, Sato Y, Ohno T, Azuma M, Kume H . Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma. PLoS One. 2018; 13(7):e0199719. PMC: 6059393. DOI: 10.1371/journal.pone.0199719. View

16.

Nunes-Xavier C, Pulido R . Global RT-PCR and RT-qPCR Analysis of the mRNA Expression of the Human PTPome. Methods Mol Biol. 2016; 1447:25-37. DOI: 10.1007/978-1-4939-3746-2_2. View

17.

Feng Y, Yang Z, Zhang C, Che N, Liu X, Xuan Y . B7-H4 induces epithelial-mesenchymal transition and promotes colorectal cancer stemness. Pathol Res Pract. 2021; 218:153323. DOI: 10.1016/j.prp.2020.153323. View

18.

Nunes-Xavier C, Karlsen K, Tekle C, Pedersen C, Oyjord T, Hongisto V . Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors. Oncotarget. 2016; 7(6):6891-901. PMC: 4872756. DOI: 10.18632/oncotarget.6902. View

19.

Flem-Karlsen K, Fodstad O, Nunes-Xavier C . B7-H3 Immune Checkpoint Protein in Human Cancer. Curr Med Chem. 2019; 27(24):4062-4086. DOI: 10.2174/0929867326666190517115515. View

20.

Nunes-Xavier C, Angulo J, Pulido R, Lopez J . A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma. Curr Urol Rep. 2019; 20(1):1. DOI: 10.1007/s11934-019-0866-8. View